From NJBIZ
Dr. Jan Schwarz-Miller, chief medical officer of Atlantic Health System, said that the new Partners in Innovation, Education and Research Consortium will help fill New Jersey’s growing need for appropriate sites in which to conduct clinical trials for new drugs.
Dr. Jan Schwarz-Miller, chief medical officer of Atlantic Health System, said that the new Partners in Innovation, Education and Research Consortium will help fill New Jersey’s growing need for appropriate sites in which to conduct clinical trials for new drugs.
The consortium, which was announced Monday, will include Drexel University, Einstein Healthcare Network, Geisinger (including AtlantiCare), Atlantic Health, Main Line Health and Thomas Jefferson University.
Schwarz-Miller said the consortium should help expedite approvals of new drugs, especially those for treating rare diseases. She said one of the difficulties in conducting clinical trials is finding the appropriate group of patients to participate in trials – a time-consuming effort that often involves immense costs.
“The challenge for pharmaceutical companies is finding the right patients to participate in those trials in a time-effective manner,” Schwarz-Miller said. “So by bringing a number of organizations together to conduct clinical trials, you’re able to quickly get the appropriate number of patients to study side-effects, efficacy, etc.”
Schwarz-Miller said the consortium should help expedite approvals of new drugs, especially those for treating rare diseases. She said one of the difficulties in conducting clinical trials is finding the appropriate group of patients to participate in trials – a time-consuming effort that often involves immense costs.
“The challenge for pharmaceutical companies is finding the right patients to participate in those trials in a time-effective manner,” Schwarz-Miller said. “So by bringing a number of organizations together to conduct clinical trials, you’re able to quickly get the appropriate number of patients to study side-effects, efficacy, etc.”
